ライフサイエンスコーパス: xenotransplantation

1 when pig cells are transplanted into humans (xenotransplantation).

2 terest in the immunotherapy of cancer and in xenotransplantation.

3 ammation and for improving graft survival in xenotransplantation.

4 itiation in anti-CD122-primed NOD/SCID mouse xenotransplantation.

5 C+/CD49e+ fraction produced tumors following xenotransplantation.

6 l progenitors remained highly malignant upon xenotransplantation.

7 ght have implications for clinical trials of xenotransplantation.

8 stained at higher levels than controls after xenotransplantation.

9 tes classic pathway complement activation in xenotransplantation.

10 eventually enable safe and effective porcine xenotransplantation.

11 play a pathophysiologic role in pig-to-human xenotransplantation.

12 ot form tumors following human-to-nude mouse xenotransplantation.

13 e requirement for immunosuppression in islet xenotransplantation.

14 a promising avenue for future approaches to xenotransplantation.

15 und using pig-to-primate heterotopic cardiac xenotransplantation.

16 cute rejection (HAR) in Gal-positive cardiac xenotransplantation.

17 rigenicity and differentiation potential via xenotransplantation.

18 ve marrow niche environment of scid mice for xenotransplantation.

19 barrier to the clinical application of islet xenotransplantation.

20 ted to aid the clinical translation of islet xenotransplantation.

21 resent a new carbohydrate moiety involved in xenotransplantation.

22 EC membrane antigens detected after cardiac xenotransplantation.

23 fer insight into new therapies for allo- and xenotransplantation.

24 A were detected in baboons following porcine xenotransplantation.

25 may be activated with immunosuppression for xenotransplantation.

26 human anti-pig cellular response is key for xenotransplantation.

27 source of transplantable organs via modified xenotransplantation.

28 y response is of significance for success in xenotransplantation.

29 nt step toward the clinical applicability of xenotransplantation.

30 ERV) is considered one of the major risks in xenotransplantation.

31 b) present major obstacles in pig-to-primate xenotransplantation.

32 d in the development of animals suitable for xenotransplantation.

33 by human complement, a model of pig-to-human xenotransplantation.

34 nt manner in a rat-to-mouse model of corneal xenotransplantation.

35 oundary that will need to be overcome within xenotransplantation.

36 stroma in the grafts for 2 months following xenotransplantation.

37 relevant, discordant, pig-to-baboon model of xenotransplantation.

38 actose (Gal) in pigs has proved a barrier to xenotransplantation.

39 but not PLHV-1, is activated in solid-organ xenotransplantation.

40 effective erythropoiesis 3 to 4 months after xenotransplantation.

41 y to be essential to the success of clinical xenotransplantation.

42 jor barrier to clinical application of organ xenotransplantation.

43 , would be one group that might benefit from xenotransplantation.

44 demonstrated after pig-to-baboon solid-organ xenotransplantation.

45 experimental protocol of pig-to-baboon heart xenotransplantation.

46 d may further enhance the safety of clinical xenotransplantation.

47 ological, scientific, and ethical nuances of xenotransplantation.

48 may not constitute a direct major barrier to xenotransplantation.

49 ing acute allograft rejection and unknown in xenotransplantation.

50 PERV may pose an infectious risk in clinical xenotransplantation.

51 regarded as the major barrier to successful xenotransplantation.

52 nment of PERV infection of human cells after xenotransplantation.

53 but has not been observed in pig-to-primate xenotransplantation.

54 ipient and frequently become activated after xenotransplantation.

55 cells, raising concerns regarding safety of xenotransplantation.

56 ment of the retroviral risks of pig to human xenotransplantation.

57 to coagulopathies observed in pig-to-primate xenotransplantation.

58 clinically relevant pig-to-primate model of xenotransplantation.

59 suggesting avoidance of sensitization after xenotransplantation.

60 ctions has been documented in pig-to-primate xenotransplantation.

61 n observed frequently in pig-to-baboon renal xenotransplantation.

62 ing of pigs, and the unique problems of lung xenotransplantation.

63 to prolong graft survival in pig-to-primate xenotransplantation.

64 t differ in average tumor size 25 days after xenotransplantation.

65 LA class I is a target for genome editing in xenotransplantation.

66 ome the humoral immune barrier that prevents xenotransplantation.

67 at may be applicable to clinical solid organ xenotransplantation.

68 hyperacute organ rejection in pig to primate xenotransplantation.

69 es a major immunologic barrier to successful xenotransplantation.

70 an ex vivo pre-clinical mouse model based on xenotransplantation.

71 Antipig antibodies are a barrier to clinical xenotransplantation.

72 ls to address the safety concern in clinical xenotransplantation.

73 topenia associated with pig-to-human hepatic xenotransplantation.

74 ibodies in IVIg could be harmful in clinical xenotransplantation.

75 uggesting that contamination occurred during xenotransplantation.

76 cytosis of platelets in pig-to-primate liver xenotransplantation.

77 associated with vascularized pig-to-primate xenotransplantation.

78 es represents a major obstacle to successful xenotransplantation.

79 for clinical application of porcine-to-human xenotransplantation.

80 nd they may represent a source of organs for xenotransplantation.

81 allow for successful clinical application of xenotransplantation.

82 One possible solution to this problem is xenotransplantation.

83 renewal, nor enhanced in vivo engraftment in xenotransplantations.

84 d open new avenues of intervention to making xenotransplantation a clinical reality.

85 The clinical applicability of porcine xenotransplantation-a long-investigated alternative to t

86 anoproteomics, stromal coculture, and BC LSC xenotransplantation analyses.

87 and culture of human tissue, bioengineering, xenotransplantation and genome editing, Induced pluripot

88 ity, to human AMR in allotransplantation and xenotransplantation and illustrates the current mechanis

89 unity to xenoantigens was only induced after xenotransplantation and not by immunization with porcine

90 f porcine endogenous retrovirus (PERV) after xenotransplantation and on the long-term immune response

91 ding the continuing debates on the ethics of xenotransplantation and the safeguards that should be im

92 This gene is responsible for generating xenotransplantation antigens resulting in hyperacute rej

93 benchmark for clinical translation of heart xenotransplantation appears within reach, carefully and

94 This humanized ossicle xenotransplantation approach provides a system for model

95 In this study, using a xenotransplantation approach, we have modeled human pedi

96 NOD/LtSz-scid IL2Rgamma null(c) (NSG) mouse xenotransplantation approaches to elucidate leukemia-ini

97 work suggests that immunological barriers to xenotransplantation are not insurmountable.

98 or producing antigens that impose limits on xenotransplantation as they are discovered.

99 Here we show that modified xenotransplantation assay conditions, including the use

100 ith overexpressed ODC in an in vivo tracheal xenotransplantation assay for epithelial cell invasivene

101 rmed the clinical relevance of the surrogate xenotransplantation assay for quantifying cells with rap

102 e combined immune-deficient (NOD/SCID) mouse xenotransplantation assay is the most commonly used surr

103 Modifications to xenotransplantation assays can therefore dramatically in

104 Furthermore, xenotransplantation assays demonstrated that a subset of

105 to drive the development of histiocytosis in xenotransplantation assays in vivo.

106 melanoma initiation in serial human-to-mouse xenotransplantation assays may be contained both among s

107 Xenotransplantation assays revealed that HSC activity is

108 However, refinements of xenotransplantation assays, alternative methods of quant

109 esponse pathway and impaired tumor growth in xenotransplantation assays.

110 ype and enhanced tumor initiating ability in xenotransplantation assays.

111 se human cells to physiologically engraft in xenotransplantation assays.

112 -forming progenitors, and LSCs as defined by xenotransplantation assays.

113 o differentiation and long-term repopulation xenotransplantation assays.

114 ary human triple-mutated AML cells in serial xenotransplantation assays.

115 tem cell pool, as measured in 6- to 12-month xenotransplantation assays.

116 f rare subpopulations of engrafting cells in xenotransplantation assays.

117 argeted leukemic stem cells in secondary AML xenotransplantation assays.

118 of the Ethics Committee of the International Xenotransplantation Association is presented.

119 of the Ethics Committee of the International Xenotransplantation Association, Sykes et al. diagram im

120 Using a robust model of xenotransplantation based on NOD/SCID/IL2Rgammac-deficie

121 optimal sources of organs for clinical organ xenotransplantation because many humans have minimal or

122 may be ideal sources of organs for clinical xenotransplantation because many humans have no preforme

123 Xenotransplantation, because of the complexity of the me

124 ogical obstacles are to be negotiated before xenotransplantation becomes a clinical reality.

125 l's ability to provide insight into not only xenotransplantation but across disciplines.

126 of this important specificity, which limits xenotransplantation by causing hyperacute and delayed xe

127 Before xenotransplantation can be introduced successfully into

128 iated inhibition of tumor growth in a murine xenotransplantation cancer model.

129 Xenotransplantation carries numerous ethical dilemmas.

130 d into primates, bringing clinical trials of xenotransplantation closer.

131 Upon xenotransplantation, edge-derived cells show a higher ca

132 -linked galactose such as the immunodominant xenotransplantation epitope Galalpha1-3Galbeta1-4GlcNAc

133 atic removal of the immunodominant alpha3Gal xenotransplantation epitope.

134 nce barriers, implying a need for caution in xenotransplantation, especially of porcine tissues.

135 In vivo, xenotransplantation experiments demonstrated that the ho

136 Xenotransplantation experiments using MPeMSCs demonstrat

137 In serial human-to-mouse xenotransplantation experiments, ABCB5+ melanoma cells p

138 studied extensively by investigators in the xenotransplantation field.

139 The potential of xenotransplantation for clinical application will requir

140 ould lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, there

141 Heterotopic cardiac xenotransplantation from alpha1,3-galactosyltransferase

142 f these observations, the safety of clinical xenotransplantation from miniature swine will be most en

143 Xenotransplantation from pigs could provide a potential

144 that composite thymokidney and thymic-tissue xenotransplantation from swine to baboons can induce don

145 To evaluate the safety of xenotransplantation further, we assessed the effect of c

146 Traditionally, xenotransplantation has been carried out using larval ze

147 Porcine islet xenotransplantation has been demonstrated in many animal

148 Xenotransplantation has been suggested as a potential so

149 Cardiac xenotransplantation has recently taken an important step

150 on, the initial immune barrier to successful xenotransplantation, has been overcome with pig donors t

151 The immunological barriers to xenotransplantation have been, and remain, formidable.

152 has reduced the antibody-mediated barrier to xenotransplantation; herein, we describe the effect that

153 Balanced against the potential benefits of xenotransplantation, however, is the risk of human infec

154 other pig tissues to levels that enable the xenotransplantation humoral barrier to be overcome.

155 be illuminated through transgenic, knockout, xenotransplantation, immunological reconstitution, drug-

156 to overcome this limitation is by human cell xenotransplantation in immune-deficient mice.

157 Xenotransplantation in mesentery of pig pancreatic primo

158 When the results of pig organ xenotransplantation in nonhuman primates suggest a reali

159 ion, we tested the feasibility of hepatocyte xenotransplantation in nonhuman primates.

160 A profound thrombocytopenia limits hepatic xenotransplantation in the pig-to-primate model.

161 of sensitized transplant recipients and for xenotransplantation in which B-cell reactivity is a pred

162 zebrafish and the first clinical trial using xenotransplantation in zebrafish larvae for phenotypic t

163 Applications such as xenotransplantation, increased livestock productivity, b

164 n cord blood (hCB) CD34(+) cells followed by xenotransplantation into immunocompromised NSG mice or N

165 taining GFP-positive oocytes 1-2 weeks after xenotransplantation into immunodeficient female mice.

166 rigenic potential of human cancer cells is a xenotransplantation into immunodeficient mice.

167 ssing human male CCA cell line (EGI-1) after xenotransplantation into severe-combined-immunodeficient

168 Xenotransplantation is a promising strategy to alleviate

169 Although islet xenotransplantation is a promising therapy for type 1 di

170 Xenotransplantation is an attractive alternative to allo

171 cine cytomegalovirus (PCMV) in pig-to-baboon xenotransplantation is associated with xenograft injury

172 Xenotransplantation is frequently used to study normal a

173 raft survival had not been achieved in islet xenotransplantation, it has been impossible to explore t

174 sing interest in the use of swine organs for xenotransplantation lend importance to the question of w

175 lation factors following pig-to-baboon liver xenotransplantation (LXT) using GalT-KO swine donors.

176 Clinical trials of xenotransplantation may be influenced by various factors

177 In summary, the success of pig-to-primate xenotransplantation may necessitate immune tolerance to

178 coagulation dysregulation in pig-to-primate xenotransplantation, may have additional benefits by neu

179 e retransplants and suggests that hepatocyte xenotransplantation might be useful as a bridge to liver

180 nviable human cardiomyocytes in this chronic xenotransplantation model (n>12; P=0.41).

181 Here we show that a xenotransplantation model bearing subcutaneous humanized

182 f-renew and to generate non-LICs in vivo The xenotransplantation model captures functional properties

183 ovide the first example of a patient-derived xenotransplantation model for a human histiocytic neopla

184 Here we report a MDS patient-derived xenotransplantation model in cytokine-humanized immunode

185 rate robust HBV and HCV infection in a novel xenotransplantation model in which large numbers of immu

186 y eradicates CML LSCs both in vitro and in a xenotransplantation model of human CML.

187 We developed a novel mouse xenotransplantation model of retinal neovascularization

188 fic NOD.Cg-Prkdc(scid) IL2rg(tmWjl)/Sz (NSG) xenotransplantation model that NK cells mediate consider

189 cells, as assessed in vivo through a murine xenotransplantation model, indicated that undifferentiat

190 In a xenotransplantation model, Mfn-2 gene therapy or Drp-1 i

191 and inhibits tumor formation in a mouse AML xenotransplantation model.

192 their successful application as donors in a xenotransplantation model.

193 AML cell lines and primary AML in an in vivo xenotransplantation model.

194 long-term tumorigenesis in a NOD/SCID serial xenotransplantation model.

195 I surface expression in vitro and in a mouse xenotransplantation model.

196 ssed ability to form germ cells in vivo in a xenotransplantation model.

197 ess-dependent chemoresistance development in xenotransplantation models and primary AML patient sampl

198 r growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumo

199 -associated diseases in vivo, human-to-mouse xenotransplantation models for human blood and blood-for

200 drug resistance and impaired tumor growth in xenotransplantation models in vivo.

201 onstitutes short-term human hematopoiesis in xenotransplantation models is usually the dominant clone

202 However, conventional mouse xenotransplantation models lack essential human-specific

203 Finally, using two xenotransplantation models of imatinib-sensitive and ima

204 Xenotransplantation models recapitulated the correspondi

205 Xenotransplantation models represent powerful tools for

206 vitro and in vivo that can be used in human xenotransplantation models to examine cancer drug target

207 antibodies prevents leukemia development in xenotransplantation models using patient-derived Ph(+) A

208 of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selec

209 mannose-binding lectin (MBL) in pig-to-human xenotransplantation models.

210 reduced tumor burden in vitro and in murine xenotransplantation models.

211 promised by the frailty of the current mouse xenotransplantation models.

212 ave demonstrated efficacy against AML LSC in xenotransplantation models.

213 nferring a survival advantage in preclinical xenotransplantation models.

214 ture and in vivo subcutaneous and orthotopic xenotransplantation models.

215 of PERV in vivo has been suggested in murine xenotransplantation models.

216 different from homogeneous tumors formed in xenotransplantation models.

217 lls, is nontoxic to the cultured cells and a xenotransplantation mouse model under the conditions stu

218 d the tumorigenic potential of NB cells in a xenotransplantation mouse model.

219 Using a xenotransplantation murine model, we showed that Vgamma9

220 hallenges and other barriers associated with xenotransplantation need to be overcome.

221 not reduce the efficiency of medulloblastoma xenotransplantation nor did systemic therapy impact tumo

222 Xenotransplantation of acute myeloid leukemia (AML) into

223 Xenotransplantation of CD34(+) cells (n = 8 patients) or

224 This is the first demonstration that xenotransplantation of characterized OECs into the prima

225 tained in culture and in tumors arising from xenotransplantation of cultured cells in mice.

226 ion envisions growing new organs in situ via xenotransplantation of developing primordia from animal

227 Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 res

228 Xenotransplantation of genetically engineered porcine ch

229 Xenotransplantation of genetically modified pig organs o

230 Xenotransplantation of hepatocytes should be explored as

231 in a mouse preclinical model of subcutaneous xenotransplantation of human cells isolated from pancrea

232 Xenotransplantation of human CTC clusters into zebrafish

233 Xenotransplantation of human eutopic endometrial tissue

234 f a genetically immunocompromised strain for xenotransplantation of human patient samples in adult ze

235 Xenotransplantation of human skin onto immunocompromised

236 e avatar mouse systems, which involve direct xenotransplantation of human tumor specimens into immuno

237 Although xenotransplantation of immunodeficient mice with human h

238 monstrated by either omental or subcutaneous xenotransplantation of liver scaffold cubes (5 x 5 x 5 m

239 Furthermore, TBI-based xenotransplantation of non-t(4;11) pre-B ALL enabled det

240 Xenotransplantation of porcine islets may be a strategy

241 might be the first patients to benefit from xenotransplantation of porcine organs.

242 Xenotransplantation of porcine tissues has the potential

243 Xenotransplantation of SCID/Beige mice with U87 cells an

244 Xenotransplantation of SF3B1 mutant HSCs leads to persis

245 Primary and secondary xenotransplantation of TAL1-rearranged leukemia allowed

246 Xenotransplantation of tumor cells with down-regulated F

247 Xenotransplantation of tumor-derived mural-like cells (G

248 Xenotransplantation offers a solution to the shortage of

249 transmission to human patients by pig tissue xenotransplantation or to study the potential pathogenes

250 owever, thrombocytopenia is also observed in xenotransplantation or xenoperfusion of other porcine or

251 r studies model protection in pig-to-primate xenotransplantation, our findings of IL-4 induction of A

252 anti-Gal antibodies as the major barrier to xenotransplantation, potentially bringing this modality

253 d to PERV in clinical use of certain porcine xenotransplantation products.

254 ransmission of PERV to recipients of porcine xenotransplantation products.

255 raised concern in the development of porcine xenotransplantation products.

256 portant implications for developing relevant xenotransplantation protocols.

257 ented the successful development of clinical xenotransplantation protocols.

258 this study shows that cellular barcoding and xenotransplantation providea useful model to study the b

259 yltransferase gene-knockout pig artery patch xenotransplantation, recipient baboons received no immun

260 ype human erythroid cell culture systems and xenotransplantation settings diminishes CHD4 levels and

261 al cells (PAEC) in two pig-to-human in vitro xenotransplantation settings.

262 ic islet transplantation and organ and islet xenotransplantation should be further explored.

263 becular bone formation and bone mass in both xenotransplantation studies and in immunocompetent mice.

264 lines and primary AML cells in vitro and in xenotransplantation studies in mice.

265 Orthotopic xenotransplantation studies revealed that control TICs f

266 We couple patient samples and xenotransplantation studies with this tractable in vitro

267 l epitopes, human-specific immune responses, xenotransplantation studies, and in vivo biomaterials ev

268 ells in vivo and for human leukemia cells in xenotransplantation studies.

269 This finding has broad implications for xenotransplantation, suggesting that porcine macrophages

270 rom umbilical cord blood (CB) as well as the xenotransplantation system that allows stable engraftmen

271 Despite the challenges facing xenotransplantation, the extreme need for donor organs a

272 ed immunologic and physiological barriers to xenotransplantation, the limitations of the current anim

273 Even though considered ideal for clinical xenotransplantation, the presence of naturally-existing

274 Here, we used xenotransplantation to assess the tumorigenic potential

275 For xenotransplantation to become a clinical reality, we nee

276 ma cells in an unbiased way following serial xenotransplantation to define their individual fate beha

277 ntly impede the translation of porcine islet xenotransplantation to sustained insulin independence cl

278 at will be necessary to minimize the risk of xenotransplantation to the recipients, their families, a

279 pigs, the most suitable donors for clinical xenotransplantation, to induce graft-versus-host disease

280 s (PERV) is a potential pathogen in clinical xenotransplantation; transmission of PERV in vivo has be

281 n anticipation of the "first-in-human" heart xenotransplantation trial, we propose a set of patient c

282 ed insulin response assay, and in vivo after xenotransplantation under the kidney capsule of streptoz

283 horts, and could therefore be candidates for xenotransplantation using GalT-KO swine donors.

284 Xenotransplantation using pigs as the source species for

285 Cardiac xenotransplantation was performed with GTKO (group 1; n=

286 strategy coupled with serial human-to-mouse xenotransplantation, we identified a subpopulation of os

287 rehensive policies governing the practice of xenotransplantation, well-informed public opinions need

288 ype, as primary tumors that formed following xenotransplantation were larger, grew faster and develop

289 afts after pig-to-baboon heterotopic cardiac xenotransplantation when the induced anti-Gal antibody r

290 d alloantibodies will also have relevance to xenotransplantation where the xenoantibodies present a f

291 ly, lends encouragement that the barriers to xenotransplantation will eventually be overcome.

292 Successful xenotransplantation will likely depend, in part, on the

293 Rag2(-/-)gammac(-/-) mice as recipients for xenotransplantation with human immune systems (humanizat

294 Xenotransplantation with pig organs offers a medium-term

295 p has over 10 years of experience in cardiac xenotransplantation with pig to baboon models, the longe

296 Ten baboons underwent xenotransplantation with transgenic pig organs.

297 ve brought dramatic progress in the field of xenotransplantation, with the development of transgenic

298 , prolonging survival of mice that underwent xenotransplantation without inducing hematologic toxicit

299 ropriate for clinical application of cardiac xenotransplantation would be approached.

300 Xenotransplantation (XTx) provides a potential solution